KNC Laboratories Co.,Ltd. (6568) AI Stock Analysis

• Market Cap: ¥9.41B
• Dividend Yield: 2.98%
• Average Volume (3M): 2.89K
• Price to Earnings (P/E): 13.7
• Beta (1Y): 0.43
• Revenue Growth: -9.60%
• EPS Growth: -38.34%
• Country: JP
• Employees: 219
• Sector: Basic Materials
• Sector Strength: 58
• Industry: Chemicals
• EPS (TTM): 1.59
• Shares Outstanding: 7,779,900
• 10 Day Avg. Volume: 3,150
• 30 Day Avg. Volume: 2,890
• PEG Ratio: -0.22
• Price to Book (P/B): 0.62
• Price to Sales (P/S): 1.02
• P/FCF Ratio: -4.61
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 69 Neutral
• Price Target: ¥1,383.00 ▲(23.04% Upside)

The stock's overall score is driven primarily by its strong financial performance and reasonable valuation. Technical analysis indicates potential short-term weakness, but longer-term trends remain positive. The lack of earnings call and corporate events data limits further insights.

Positive Factors

Strong balance sheet / low leverage

A consistently high equity ratio and low debt-to-equity provide durable financial flexibility, lowering refinancing risk and enabling the company to fund R&D, capital projects, or absorb cyclical revenue shocks without needing immediate external financing.

Solid cash conversion from operations

Strong operating cash flow relative to net income indicates reliable cash generation from core operations. This supports recurring service contracts, working capital needs, and can sustain investment in instruments and reagents even if free cash flow is temporarily impacted by capex.

Historically stable gross margins and prior revenue growth

Multi-year revenue expansion and stable gross margins point to durable product pricing power and diversified end markets (academia, pharma). This structural margin stability supports long-term profitability even during short-term top-line variability.

Negative Factors

Recent revenue decline (2025)

A top-line decline in the most recent period signals potential demand softness or competitive erosion. If sustained, this reduces scale benefits, pressures fixed-cost absorption, and can constrain reinvestment into R&D and customer-support capabilities.

Negative free cash flow driven by high capex

Sustained negative free cash flow from elevated capital spending reduces financial flexibility despite low leverage. Over time this can force slower growth, higher external financing needs, or reprioritization of maintenance and customer-facing investments.

Earnings and margin pressure / EPS decline

A marked EPS decline and recent dip in operating and net margins indicate weakening profitability or rising costs. Persisting margin pressure erodes return on equity and may necessitate restructuring, price increases, or reduced investment in product development.

KNC Laboratories Co.,Ltd. Business Overview & Revenue Model

Company Description

KNC Laboratories Co., Ltd. engages in the research, development, and production solutions of organic chemicals in Japan. The company offers products for use in the pharmaceutical, electronic-chemical, agrochemical, energy, and environment fields. It offers support services for drugs and functional chemicals. The company was incorporated in 1985 and is headquartered in Kobe, Japan.

How the Company Makes Money

KNC Laboratories generates revenue through the sale of its laboratory instruments and reagents, which are essential for various scientific and industrial applications. The company has multiple key revenue streams, including direct sales of products, service contracts for maintenance and support, and collaborations with research institutions and pharmaceutical companies for custom product development. Strategic partnerships with industry leaders also contribute significantly to the company's earnings, enabling it to leverage complementary technologies and expand its market reach. Additionally, KNC Laboratories may benefit from grants and funding for research projects, further enhancing its financial stability.

KNC Laboratories Co.,Ltd. Financial Statement Overview

Summary

The company has shown strong revenue growth over the years, but a recent decline in 2025. The balance sheet is solid with low leverage and high equity, though negative free cash flow due to high capital expenditures is a concern.

Income Statement

The company has shown strong revenue growth over the years with a notable increase from 2020 to 2024. However, the latest period (2025) saw a decline in revenue compared to 2024. Gross profit margins have been relatively stable, but EBIT and net profit margins saw a dip in the most recent year, indicating some pressure on profitability.

Balance Sheet

The company maintains a solid equity base with a consistent equity ratio above 65%. The debt-to-equity ratio is low, suggesting prudent leverage management. Return on equity is reasonable, though it has decreased slightly in the latest year, which could indicate some efficiency challenges.

Cash Flow

Operating cash flow to net income ratio is strong, reflecting good conversion of earnings to cash. However, free cash flow has been negative in the latest periods, primarily due to high capital expenditures. This poses potential risks if not managed carefully.

Breakdown	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	8.18B	9.15B	8.63B	7.44B	6.03B
Gross Profit	2.32B	3.30B	3.30B	2.11B	1.76B
EBITDA	1.83B	3.02B	3.10B	1.86B	1.54B
Net Income	737.33M	1.49B	1.54B	643.46M	399.68M
Balance Sheet
Total Assets	20.15B	18.62B	15.40B	13.95B	12.78B
Cash, Cash Equivalents and Short-Term Investments	2.39B	3.31B	2.30B	1.97B	1.96B
Total Debt	3.12B	1.97B	1.54B	1.68B	1.44B
Total Liabilities	6.63B	5.53B	3.66B	3.38B	2.66B
Stockholders Equity	13.52B	13.09B	11.75B	10.58B	10.12B
Cash Flow
Free Cash Flow	-1.82B	850.16M	863.73M	-248.27M	434.68M
Operating Cash Flow	1.49B	3.20B	1.99B	585.11M	1.33B
Investing Cash Flow	-3.32B	-2.37B	-1.15B	-613.51M	-660.05M
Financing Cash Flow	909.60M	178.87M	-523.39M	39.02M	-180.14M

KNC Laboratories Co.,Ltd. Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 1124.00
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Positive
• RSI: Neutral
• STOCH: Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For JP:6568, the sentiment is Positive. The current price of 1124 is below the 20-day moving average (MA) of 1223.65, below the 50-day MA of 1156.24, and above the 200-day MA of 1097.07, indicating a neutral trend. The MACD of 22.68 indicates Positive momentum. The RSI at 54.13 is Neutral, neither overbought nor oversold. The STOCH value of 7.54 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for JP:6568.

KNC Laboratories Co.,Ltd. Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
4040	77 Outperform	¥7.32B	6.31	―	1.96%	8.43%	2.99%
4531	72 Outperform	¥8.49B	12.65	―	2.97%	9.92%	-27.64%
4366	71 Outperform	¥12.29B	14.22	―	1.81%	9.07%	―
4960	71 Outperform	¥12.82B	134.39	―	1.06%	-9.63%	-1.71%
6568	69 Neutral	¥9.41B	13.68	―	2.98%	-9.60%	-38.34%
9227	62 Neutral	¥16.05B	-73.25	―	―	-16.76%	74.95%
Sector *	61 Neutral	$10.43B	7.12	-0.05%	2.87%	2.86%	-36.73%